Safety Profile of Selective Serotonin Reuptake Inhibitors in Real-World Settings: A Pharmacovigilance Study Based on FDA Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Most of our findings are consistent with those reported previously, but some AEs were not previously identified. However, AEs attributed to SSRIs remain ambiguous, warranting further validation. Applying data-mining methods to the FAERS database can provide additional insights that can assist in appropriately utilizing SSRIs.PMID:38407147 | DOI:10.1177/10600280241231116
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Yi Zhao Yuzhou Zhang Lin Yang Kanghuai Zhang Sha Li Source Type: research
More News: Celexa | Citalopram | Databases & Libraries | Depression | Drugs & Pharmacology | Fluoxetine | Genetics | Lexapro | Paroxetine | Paxil | Prozac | Psychiatry | Sertraline | Study | Zoloft